CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study - Concepedia

Concepedia

Publication | Open Access

CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

DOI Full Paper Access

35

Citations

23

References

2021

Year

Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens, Nataliya V. Uboha, Patrick A. Ott, Patricia LoRusso, Javier García-Corbacho, Valentina Boni, Johanna C. Bendell,

Journal for ImmunoTherapy of Cancer

Abstract

NCT03013491.

References

	Year	Citations

Page 1